Johnson & Johnson (FRA:JNJ)
€ 138.92 -0.18 (-0.13%) Market Cap: 334.68 Bil Enterprise Value: 341.56 Bil PE Ratio: 9.88 PB Ratio: 5.15 GF Score: 83/100

Johnson & Johnson at SVB Securities Global Biopharma Conference (Virtual) Transcript

Feb 15, 2023 / 06:00PM GMT
Release Date Price: €149.5 (-1.23%)
David Reed Risinger
SVB Securities LLC, Research Division - Senior MD

Great. Good afternoon, everyone, and thank you for joining us for this next session with JNJ. My name is Dave Risinger, and I cover diversified biopharmaceuticals. It's very much my pleasure to welcome 2 senior leaders at Johnson & Johnson. So that is Biljana Naumovic. She is Worldwide President of Global Oncology; and also Peter Lebowitz, who's Global Therapeutic Head of Oncology R&D.

Questions & Answers

David Reed Risinger
SVB Securities LLC, Research Division - Senior MD

So I thought we'd start off with a high-level question for Biljana. Could you discuss -- well, first of all, congrats on all of the phenomenal progress and momentum for your organization and what you're leading. I thought we'd start off with asking you to discuss your vision for capitalizing on the tremendous success that you've already had and driving further success in multiple myeloma.

Biljana Naumovic

Thank you, David. And it's really a pleasure to be with you

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot